# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Leonid Timashev reiterates Compass Pathways (NASDAQ:CMPS) with a Outperform and maintains $23 price target.
Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.
Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy.
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI adva...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...
Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target fr...